文献速递心境障碍焦虑、强迫与应激相关障碍会诊联络精神医学

经前烦躁障碍或经前综合征与心境障碍共病的系统综述与荟萃分析

A systematic review and meta-analysis on the comorbidity of premenstrual dysphoric disorder or premenstrual syndrome with mood disorders: prevalence, clinical and neurobiological correlates.
PubMed 文献 · Br J Psychiatry · 2025-07-11

该系统综述与荟萃分析纳入39项研究(其中36项、n=3646进入荟萃分析),评估PMDD/PMS与成人非生殖类心境障碍的共病率。随机效应模型显示,不同诊断采样策略下共病率一致较高,范围为42%(95%CI:30%,55%)至49%(95%CI:38%,60%)。

要点

  • PMDD/PMS与心境障碍共病率高达42%–49%,不受诊断采样策略影响。
  • 共病可能影响临床病程,但相关神经生物学证据仍需进一步研究。
  • 研究异质性高、多依赖横断面设计且PMDD/PMS诊断为暂时性,限制证据强度。

核心结论

  • 无论采用何种诊断采样策略,PMDD/PMS与心境障碍的共病率均较高,范围为42%(95%CI:30%,55%)至49%(95%CI:38%,60%)。

研究设计与样本

  • 系统综述与荟萃分析,检索Embase、MEDLINE和APA PsycINFO自建库至2024年1月22日,纳入39项研究,其中36项(n=3646)进入荟萃分析。
  • 纳入标准为诊断为PMDD/PMS且共病心境障碍的女性,采用随机效应模型合并患病率,并按心境障碍先诊断、PMDD/PMS先诊断或同时诊断分类。

主要发现

  • 7项研究聚焦双相障碍,18项聚焦单相抑郁障碍,14项为双相与单相混合样本。
  • 随机效应荟萃分析显示PMDD/PMS与心境障碍的共病率在不同采样策略下均较高,范围为42%(95%CI:30%,55%)至49%(95%CI:38%,60%)。
  • 偏倚风险不一,研究方法存在异质性;叙述性综合探讨了疾病病程和生物标志物等次要结局。

关键数值与推荐

  • PMDD/PMS与心境障碍的合并共病率范围为42%(95%CI:30%,55%)至49%(95%CI:38%,60%)。

临床怎么用

  • 临床中应对心境障碍女性常规评估PMDD/PMS共病,反之亦然。
  • 共病率高提示需针对该人群制定个体化诊断与治疗策略。

局限性

  • 研究间存在异质性,方法学异质性明显。
  • 多数研究依赖横断面设计,且PMDD/PMS诊断为暂时性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mood disorders are among the leading causes of disease burden worldwide, with 20-70% of affected individuals experiencing comorbid premenstrual disorders. This systematic review and meta-analysis investigated the comorbidity of premenstrual dysphoric disorder (PMDD) or premenstrual syndrome (PMS) with non-reproductive mood disorders. AIMS: We aimed to determine the pooled prevalence of PMDD/PMS with adult mood disorders, assess the impact of comorbidity on clinical course and summarise the associated neurobiological findings. METHOD: Eligible studies were identified through Embase, MEDLINE and APA PsycINFO from inception to 22 January 2024 (PROSPERO, no. CRD42021246796). Studies on women ('females') with diagnoses of PMDD/PMS and mood disorders were included. Risk of bias was assessed using National Institutes of Health quality assessment tools. A random-effects, pooled-prevalence meta-analysis was conducted using the Comprehensive Meta-Analysis software, categorising diagnostic sampling strategies as follows: mood disorders diagnosed first, PMDD/PMS diagnosed first or concurrent diagnoses. A narrative synthesis explored secondary outcomes, including illness course and biomarkers. RESULTS: A total of 39 studies were included, with 36 of these (n = 3646) contributing to the meta-analysis. Seven studies focused on bipolar disorders, 18 on unipolar depressive disorders and 14 on mixed samples of bipolar and unipolar disorders. Random-effects pooled-prevalence meta-analyses showed consistently high comorbidity rates between PMDD/PMS and mood disorders, ranging from 42% (95% CI: 30%, 55%) to 49% (95% CI: 38%, 60%) across sampling strategies. Risk of bias varied, with methodological heterogeneity noted. CONCLUSIONS: This review underscores high comorbidity rates between PMDD/PMS and mood disorders, regardless of sampling strategy, and highlights the need for research into clinical and neurobiological characteristics specific to this comorbidity. Limitations include study heterogeneity, reliance on cross-sectional designs and provisional PMDD/PMS diagnoses. Future research should address these gaps to inform diagnostic and therapeutic advancements tailored to this population.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bengi D, Strawbridge R, Drorian M, et al. A systematic review and meta-analysis on the comorbidity of premenstrual dysphoric disorder or premenstrual syndrome with mood disorders: prevalence, clinical and neurobiological correlates. Br J Psychiatry. 2025. PMID: 40641141. doi:10.1192/bjp.2025.133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。